Follicular lymphoma: 2011 update on diagnosis and management

American Journal of Hematology

Volumn 86, Issue 9, 2011, Pages 768-775

  Freedman, Arnold ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; HEMOGLOBIN; IBRITUMOMAB TIUXETAN; LACTATE DEHYDROGENASE; LENALIDOMIDE; MITOXANTRONE; PARAPROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ADVANCED CANCER; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASYMPTOMATIC DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CYTOPENIA; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE TRANSLOCATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE BIOPSY; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; NEOPLASM STAGING; PROGNOSIS; RECURRENCE;

EID: 80051725416     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22099     Document Type: Article

References (109)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-2795.
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
4. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002; 99: 4265-4275.
5. WHO Classification of tumours of haematopoietic and lymphoid tissues, IARC, 2008.
6. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99: 3806-3812.
7. Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program 2005: 314-320.
8. Montoto S, Fitzgibbon J. Transformation of Indolent B-Cell Lymphomas. J Clin Oncol 2011; 29: 1827-1834.
9. Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol 2010; 28: 2902-2913.
10. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
11. Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301-307.
12. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957-2964.
13. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
14. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555-4562.
15. Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
16. Anderson JR, Vose JM, Bierman PJ, et al. Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group. J Clin Oncol 1993; 11: 218-224.
17. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363-2367.
18. Rodriguez J, McLaughlin P, Hagemeister FB, et al. Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93: 2202-2207.
19. Chau I, Jones R, Cunningham D, et al. Outcome of follicular lymphoma grade 3: Is anthracycline necessary as front-line therapy? Br J Cancer 2003; 89: 36-42.
20. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350-5357.
21. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440-446.
22. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-2174.
23. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25: 390-398.
24. Klapper W, Hoster E, Rolver L, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: The German Low Grade Lymphoma Study Group. J Clin Oncol 2007; 25: 3330-3336.
25. Kuppers R. Prognosis in follicular lymphoma-It's in the microenvironment. N Engl J Med 2004; 351: 2152-2153.
26. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052-5059.
27. Wahlin BE, Sander B, Christensson B, et al. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13: 388-397.
28. Friedberg J, Huang J, Dillon H, et al. Initial therapeutic strategy in follicular lymphoma: An analysis from the National LymphoCare Study. J Clin Oncol 2006; 24: 428s.
29. Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64: 928-934.
30. Kelsey SM, Newland AC, Hudson GV, et al. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 1994; 11: 19-25.
31. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454-1459.
32. Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: A Surveillance, Epidemiology, and End Results database analysis. Cancer 2010; 116: 3843-3851.
33. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 2003; 362: 516-522.
34. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110-1117.
35. Ardeshna K, Smith P, Qian W, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010; 116:abstract 6.
36. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019-5026.
37. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452.
38. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
39. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
40. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
41. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III Study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
42. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-4831.
43. Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114:abstract 405.
44. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694-704.
45. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000; 27: 37-41.
46. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001; 97: 101-106.
47. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416-4423.
48. Hainsworth JD, Burris HA, III, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052-3056.
49. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 1103-1108.
50. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28: 4480-4484.
51. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27: 1607-1614.
52. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
53. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
54. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: A phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008; 9: 352-358.
55. Jacobs SA, Swerdlow SH, Kant J, et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008; 14: 7088-7094.
56. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005; 23: 5696-5704.
57. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24: 4143-4149.
58. Link BK, Martin P, Kaminski MS, et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010; 28: 3035-3041.
59. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.
60. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood 2005; 105: 3817-3823.
61. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667-2674.
62. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540-2544.
63. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004-4013.
64. Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009; 113: 995-1001.
65. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
66. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295-3301.
67. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853-2858.
68. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
69. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204-210.
70. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol, 2008; 26: 4473-4479.
71. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-3389.
72. Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006; 106: 2412-2420.
73. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009; 27: 5023-5030.
74. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391-398.
75. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565-7573.
76. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804-1810.
77. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
78. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005; 23: 7985-7993.
79. Ganem G, Cartron G, Girinsky T, et al. Localized low-dose radiotherapy for follicular lymphoma: History, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys 2010; 78: 975-982.
80. Luthy SK, Ng AK, Silver B, et al. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol 2008; 19: 2043-2047.
81. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J Clin Oncol 2007; 25: 2554-2559.
82. Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-450.
83. Cao TM, Horning S, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294-301.
84. Safar V, Gastinne T, Milpied N, et al. Very long term follow-up of autologous stem cell transplantation in follicular lymphoma: A retrospective single-institution experience. Ann Oncol 2008; 19: 183.
85. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257-3262.
86. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918-3927.
87. Pettengell R, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J Clin Oncol 2010; 28: 574 abtract 8005.
88. van Besien K, Loberiza FR, Jr., Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521-3529.
89. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-5536.
90. Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236-245.
91. Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 538-545.
92. Leonard JP, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007; 18: 1216-1223.
93. Bence-Bruckler I, Macdonald D, Stiff P, et al. A phase 2, double-blind, placebo-controlled trial of rituximab + galiximab vs rituximab + placebo in advanced follicular non-Hodgkin's lymphoma (NHL) Blood 2010; 116:abstract 428.
94. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008; 113: 2714-2723.
95. Grant B, Leonard J, Johnson J, et al. Combination biologic therapy as initial treatment for follicular lymphoma: Initial results from CALGB 50701-a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20). Blood 2010;116:abstract 427.
96. Freedman A, Kuruvilla J, Assouline S, et al. Clinical activity of Lucatumumab (HCD122) in patients (pts) with relapsed/refractory Hodgkin or non-Hodgkin lymphoma treated in a Phase Ia/II Clinical Trial (NCT00670592). Blood 2010; 116:abstract 284.
97. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase 1/2 trial. Blood 2008; 111: 5486-5495.
98. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 2009; 27: 3346-3353.
99. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010; 21: 1870-1876.
100. Salles G, Morschhauser F, Thieblemont C, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients-Updated results with encouraging progression free survival (PFS) data From a phase II study in patients with relapsed/refractory indolent NHL (iNHL). Blood 2010; 116:abstract 2868.
101. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002; 117: 828-834.
102. Friedberg JW, Kelly JL, Neuberg D, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009; 146: 282-291.
103. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105: 489-495.
104. Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: The old and the new. Semin Hematol 2008; 45: S2-S6.
105. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009; 27: 3036-3043.
106. Neelapu SS, Gause BL, Nikcevich DA, et al. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: Protocol summary and interim report. Clin Lymphoma 2005; 6: 61-64.
107. Kahl B, Byrd J, Flinn I, et al. Clinical safety and activity in a Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010; 116:abstract 1777.
108. Fowler F, Porte Sharman J, Smith S, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a phase I study. Blood 2010; 116:abstract 964.
109. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.